北美地尔硫卓市场预测至 2028 年 - COVID-19 影响和按产品类型(胶囊、注射剂和片剂)和应用(心绞痛、高血压等)进行的区域分析

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028


No. of Pages: 117    |    Report Code: TIPRE00025364    |    Category: Life Sciences

North America Diltiazem Market

市场介绍

地尔硫卓是一种苯并硫氮杂卓衍生物,具有抗高血压和血管扩张作用。地尔硫卓是一种抗高血压和血管扩张剂,通过放松血管肌肉来降低血压。这是由于降低血压具有长期治疗作用,因为它降低了致命和非致命心血管事件(如中风和心肌梗塞)的风险。根据体外结合实验,地尔硫卓与血浆蛋白的结合率为70%-80%。在临床相关浓度下,大约 40% 的药物被认为与 α-1-糖蛋白结合,而大约 30% 的药物被认为与白蛋白结合。

市场概况与动态

北美地尔硫卓市场预计将达到到 2028 年,将从 2021 年的 1.6153 亿美元增至 3.6922 亿美元;预计 2021 年至 2028 年复合年增长率为 12.5%。政府推广举措的增加、心血管疾病患病率的增加以及全球患有心脏病的老年人口的增加预计将推动市场增长年。然而,地尔硫卓对消费的副作用可能会对未来几年的市场增长产生负面影响。

地尔硫卓具有治疗多种心血管疾病的潜在用途。据世界卫生组织称,心血管疾病(CVD)是全球第一大死亡原因。心血管疾病是发病的主要原因,影响的人数比任何其他疾病都多。吸烟、不健康饮食和缺乏身体活动是增加心脏病和中风风险的主要生活方式因素。此外,其他可能导致心血管疾病的危险因素还有高血压、糖尿病和胆固醇水平升高。美国疾病控制与预防中心 (CDC) 估计,2019 年美国约有 27-61 万人患有心房颤动 (AFib)。每年,美国有超过 454,000 人因 AFib 住院治疗,约 158,000 人死亡。我们。钙通道阻滞剂地尔硫卓(Cardizem)和维拉帕米(Calan 和 Apoptin)可有效控制房颤患者的初始心室率。这些药物以推注剂量静脉内给药,直到心室率变慢。

此外,地尔硫卓可减少房室结的传导,这对于患有以下疾病的患者的心率控制也很有用:心房颤动。因此,全球心房颤动患病率的不断上升推动了地尔硫卓市场的发展。此外,老年人群更容易出现非典型表现、合并症和不良结果。与衰老相关的心血管系统的结构和功能变化是心血管疾病的主要原因。因此,全球老年人口的增加导致心血管疾病发病率增加,从而促进了地尔硫卓市场的增长。

在北美,美国受到的影响很大由于 COVID-19 大流行的爆发。 COVID-19 大流行引发了对于提供更好护理至关重要的技术变革。考虑到当前的大流行和实用性的需要,这些药物最好应该获得 FDA 批准,以便它们可以迅速重新用于 COVID-19 治疗。 SARS-CoV 需要 Ca2+ 离子才能进入宿主细胞,并且基于 SARS-CoV 和 SARS-CoV-2 之间的联系,很可能这两种病毒都存在确切的必需品。此外,根据bioRxiv于2020年7月发表的最新报告,有证据表明钙通道阻滞剂(CCB)在细胞进入水平上抑制病毒感染。因此,维拉帕米或地尔硫卓治疗可抑制病毒感染。高血压是 COVID-19 感染患者常见的合并症之一。地尔硫卓可能有助于治疗与 COVID-19 相关的高血压。自从COVID-19疫情达到大流行状态以来,整个全球供应链都受到了影响;然而,多家制药公司正在开发疫苗和药物来对抗这一流行病。因此,COVID-19对地尔硫卓市场产生了实质性的积极影响。

 

Key市场细分

根据产品,北美地尔硫卓市场分为胶囊剂、注射剂和片剂。 2021年,平板电脑细分市场占据最大市场份额。然而,预计2021年至2028年胶囊细分市场的复合年增长率最快。

根据应用,北美地尔硫卓市场分为心绞痛、高血压等。 2021年,高血压细分市场占据最大市场份额。预计未来几年心绞痛细分市场将以最快的复合年增长率增长。

 

< span>主要来源和上市公司

与本北美地尔硫卓市场报告相关的一些主要和二手来源是美国国家食品与食品管理局药物管理局 (USFDA)、疾病控制与预防中心 (CDC)、美国卫生与公众服务部 (HHS) 和加拿大健康研究院 (CIHR) 等。

 

购买报告的理由

  • 根据未来几年北美地尔硫卓市场的详细趋势分析确定潜在投资领域。
  • 深入了解推动支出最高的国家/地区不同成瘾治疗药物细分市场需求的根本因素,并确定他们各自提供的机会。
  • 加强您对市场需求驱动因素、行业趋势和最新技术发展等方面的了解。< /li>
  • 确定推动北美地尔硫卓市场的主要渠道提供清晰的未来机会图景,帮助分析,从而增加收入。
  • 通过关注不同国家/地区正在进行的项目来引导资源 北美地尔硫卓市场

 

北美地尔硫卓市场细分

按产品类型

  • 片剂
  • 胶囊
  • 注射剂

< span>按

应用

  • 高血压
  • 心绞痛
  • 其他

按国家/地区

  • 美国
  • 加拿大
  • 墨西哥< /li>

公司简介

  • Bausch Health Companies Inc.
  • 梯瓦制药工业有限公司
  • MYLAN NV
  • 辉瑞公司< /li>
  • 山德士(诺华公司)
  • Sun Pharmaceutical Industries Ltd
  • Hikma Pharmaceuticals PLC< /span>
  • Zydus Cadila
  • 格伦马克
  • Athenex< /li>

 

 

North America Diltiazem Strategic Insights

Strategic insights for North America Diltiazem involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/north-america-diltiazem-market-strategic-framework.webp
Get more information on this report

North America Diltiazem Report Scope

Report Attribute Details
Market size in 2021 US$ 161.53 Million
Market Size by 2028 US$ 369.22 Million
Global CAGR (2021 - 2028) 12.5%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By 产品类型
  • 胶囊
  • 注射剂
  • 片剂
By 应用
  • 心绞痛
  • 高血压
Regions and Countries Covered 北美
  • 美国
  • 加拿大
  • 墨西哥
Market leaders and key company profiles
  • Bausch Health Companies Inc.
  • Teva Pharmaceutical Industries Ltd
  • MYLAN N.V.
  • Pfizer Inc.
  • Sandoz (Novartis AG)
  • Sun Pharmaceutical Industries Ltd
  • Hikma Pharmaceuticals PLC
  • Zydus Cadila
  • Glenmark
  • Athenex
  • Get more information on this report

    North America Diltiazem Regional Insights

    The regional scope of North America Diltiazem refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/north-america-diltiazem-market-geography.webp
    Get more information on this report

    The List of Companies - North America Diltiazem Market

    1. Bausch Health Companies Inc.
    2. Teva Pharmaceutical Industries Ltd
    3. MYLAN N.V.
    4. Pfizer Inc.
    5. Sandoz (Novartis AG)
    6. Sun Pharmaceutical Industries Ltd
    7. Hikma Pharmaceuticals PLC
    8. Zydus Cadila
    9. Glenmark
    10. Athenex
    Frequently Asked Questions
    How big is the North America Diltiazem Market?

    The North America Diltiazem Market is valued at US$ 161.53 Million in 2021, it is projected to reach US$ 369.22 Million by 2028.

    What is the CAGR for North America Diltiazem Market by (2021 - 2028)?

    As per our report North America Diltiazem Market, the market size is valued at US$ 161.53 Million in 2021, projecting it to reach US$ 369.22 Million by 2028. This translates to a CAGR of approximately 12.5% during the forecast period.

    What segments are covered in this report?

    The North America Diltiazem Market report typically cover these key segments-

  • 产品类型 (胶囊, 注射剂, 片剂)
  • 应用 (心绞痛, 高血压)
  • What is the historic period, base year, and forecast period taken for North America Diltiazem Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Diltiazem Market report:

  • Historic Period : 2019-2020
  • Base Year : 2021
  • Forecast Period : 2022-2028
  • Who are the major players in North America Diltiazem Market?

    The North America Diltiazem Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Bausch Health Companies Inc.
  • Teva Pharmaceutical Industries Ltd
  • MYLAN N.V.
  • Pfizer Inc.
  • Sandoz (Novartis AG)
  • Sun Pharmaceutical Industries Ltd
  • Hikma Pharmaceuticals PLC
  • Zydus Cadila
  • Glenmark
  • Athenex
  • Who should buy this report?

    The North America Diltiazem Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the North America Diltiazem Market value chain can benefit from the information contained in a comprehensive market report.